A phase I/II trial of bortezomib combined concurrently with gemcitabine for relapsed or refractory DLBCL and peripheral T-cell lymphomas

British Journal of Haematology

Volumn 163, Issue 1, 2013, Pages 55-61

  Evens, Andrew M ^a   Rosen, Steven T ^b   Helenowski, Irene ^b   Kline, Justin ^c   Larsen, Annette ^d   Colvin, Jennifer ^d   Winter, Jane N ^b   van Besien, Koen M ^e   Gordon, Leo I ^b   Smith, Sonali M ^c  

^a TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b NORTHWESTERN UNIVERSITY   (United States)

^c UNIVERSITY OF CHICAGO   (United States)

^d UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL   (United States)

^e WEILL CORNELL MEDICAL COLLEGE   (United States)

Author keywords

Bortezomib; Diffuse large B cell lymphoma; Gemcitabine; Lymphoma; Peripheral T cell lymphoma

Indexed keywords

BORTEZOMIB; GEMCITABINE;

ADULT; AGED; ALKALINE PHOSPHATASE BLOOD LEVEL; ANEMIA; ANOREXIA; ARTICLE; BLEEDING; BRAIN DYSFUNCTION; CANCER COMBINATION CHEMOTHERAPY; CANCER RECURRENCE; CLINICAL ARTICLE; CLINICAL TRIAL; CONGENITAL SKIN DISEASE; CONSTIPATION; COUGHING; CREATININE BLOOD LEVEL; DEHYDRATION; DIARRHEA; DOSE RESPONSE; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG FEVER; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG TOLERABILITY; DYSPEPSIA; DYSPNEA; EDEMA; FATIGUE; FEMALE; HEART DISEASE; HUMAN; HYPERBILIRUBINEMIA; HYPERGLYCEMIA; HYPERTENSION; HYPERTRANSAMINASEMIA; HYPOALBUMINEMIA; HYPOCALCEMIA; HYPOKALEMIA; HYPONATREMIA; INFECTION; INTENTION TO TREAT ANALYSIS; LARGE CELL LYMPHOMA; LEUKOPENIA; LIVER FUNCTION TEST; LYMPHOCYTOPENIA; MALE; MAXIMUM TOLERATED DOSE; NAUSEA; NEUTROPENIA; OVERALL SURVIVAL; PAIN; PERIPHERAL T CELL LYMPHOMA; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; POTASSIUM DEFICIENCY; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; SIDE EFFECT; THROMBOCYTOPENIA; TREATMENT FAILURE; TREATMENT OUTCOME; VOMITING; WEIGHT CHANGE;

BORTEZOMIB; DIFFUSE LARGE B-CELL LYMPHOMA; GEMCITABINE; LYMPHOMA; PERIPHERAL T-CELL LYMPHOMA;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BORONIC ACIDS; DEOXYCYTIDINE; FEMALE; HUMANS; LYMPHOMA, LARGE B-CELL, DIFFUSE; LYMPHOMA, T-CELL, PERIPHERAL; MALE; MIDDLE AGED; PYRAZINES; RECURRENCE; TREATMENT OUTCOME;

EID: 84883788729     PISSN: 00071048     EISSN: 13652141     Source Type: Journal    
DOI: 10.1111/bjh.12488     Document Type: Article

References (40)

1. Arkenau, H.T., Chong, G., Cunningham, D., Watkins, D., Sirohi, B., Chau, I., Wotherspoon, A., Norman, A., Horwich, A. & Matutes, E. (2007) Gemcitabine, cisplatin and methylprednisolone for the treatment of patients with peripheral T-cell lymphoma: the Royal Marsden Hospital experience. Haematologica, 92, 271-272.
2. Awasthi, N., Schwarz, M.A. & Schwarz, R.E. (2009) Proteasome inhibition enhances antitumour effects of gemcitabine in experimental pancreatic cancer. HPB (Oxford), 11, 600-605.
3. Awasthi, N., Schwarz, M.A. & Schwarz, R.E. (2010) Combination effects of bortezomib with gemcitabine and EMAP II in experimental pancreatic cancer. Cancer Biology & Therapy, 10, 99-107.
4. Bommakanti, S.V., Dudek, A.Z., Khatri, A., Kirstein, M.N. & Gada, P.D. (2011) Phase 1 trial of gemcitabine with bortezomib in elderly patients with advanced solid tumors. American Journal of Clinical Oncology, 34, 597-602.
5. Ceresa, C., Giovannetti, E., Voortman, J., Laan, A.C., Honeywell, R., Giaccone, G. & Peters, G.J. (2009) Bortezomib induces schedule-dependent modulation of gemcitabine pharmacokinetics and pharmacodynamics in non-small cell lung cancer and blood mononuclear cells. Molecular Cancer Therapeutics, 8, 1026-1036.
6. Cheson, B.D., Horning, S.J., Coiffier, B., Shipp, M.A., Fisher, R.I., Connors, J.M., Lister, T.A., Vose, J., Grillo-Lopez, A., Hagenbeek, A., Cabanillas, F., Klippensten, D., Hiddemann, W., Castellino, R., Harris, N.L., Armitage, J.O., Carter, W., Hoppe, R. & Canellos, G.P. (1999) Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. NCI Sponsored International Working Group. Journal of Clinical Oncology, 17, 1244.
7. Crump, M., Baetz, T., Couban, S., Belch, A., Marcellus, D., Howson-Jan, K., Imrie, K., Myers, R., Adams, G., Ding, K., Paul, N., Shepherd, L., Iglesias, J. & Meyer, R. (2004) Gemcitabine, dexamethasone, and cisplatin in patients with recurrent or refractory aggressive histology B-cell non-Hodgkin lymphoma: a Phase II study by the National Cancer Institute of Canada Clinical Trials Group (NCIC-CTG). Cancer, 101, 1835-1842.
8. Davies, A.M., Chansky, K., Lara, P.N. Jr, Gumerlock, P.H., Crowley, J., Albain, K.S., Vogel, S.J. & Gandara, D.R. (2009) Bortezomib plus gemcitabine/carboplatin as first-line treatment of advanced non-small cell lung cancer: a phase II Southwest Oncology Group Study (S0339). Journal of Thoracic Oncology, 4, 87-92.
9. Davies, A.M., Lara, P.N., Lau, D.H., Mack, P.C., Gumerlock, P.H., Gandara, D. R., Schenkein, D. & Doroshow, J.H. (2004) The proteasome inhibitor, bortezomib, in combination with gemcitabine (Gem) and carboplatin (Carbo) in advanced non-small cell lung cancer (NSCLC): Final results of a phase I California Cancer Consortium study. Journal of Clinical Oncology (ASCO Meeting Abstracts), 22, (Suppl. 14S), abstract 7106.
10. Dong, M., He, X.H., Liu, P., Qin, Y., Yang, J.L., Zhou, S.Y., Yang, S., Zhang, C.G., Gui, L., Zhou, L.Q. & Shi, Y.K. (2013) Gemcitabine-based combination regimen in patients with peripheral T-cell lymphoma. Medical Oncology, 30, 351.
11. El Gnaoui, T., Dupuis, J., Belhadj, K., Jais, J.P., Rahmouni, A., Copie-Bergman, C., Gaillard, I., Divine, M., Tabah-Fisch, I., Reyes, F. & Haioun, C. (2007) Rituximab, gemcitabine and oxaliplatin: an effective salvage regimen for patients with relapsed or refractory B-cell lymphoma not candidates for high-dose therapy. Annals of Oncology, 18, 1363-1368.
12. Emmanouilides, C., Colovos, C., Pinter-Brown, L., Hernandez, L., Schiller, G., Territo, M. & Rosen, P. (2004) Pilot study of fixed-infusion rate gemcitabine with Cisplatin and dexamethasone in patients with relapsed or refractory lymphoma. Clinical Lymphoma, 5, 45-49.
13. Espinosa, I., Briones, J., Bordes, R., Brunet, S., Martino, R., Sureda, A., Sierra, J. & Prat, J. (2008) Activation of the NF-kappaB signalling pathway in diffuse large B-cell lymphoma: clinical implications. Histopathology, 53, 441-449.
14. Evens, A.M. & Gartenhaus, R.B. (2003) Molecular etiology of mature T-cell non-Hodgkin's lymphomas. Frontiers in Bioscience, 8, d156-d175.
15. Evens, A.M. & Gartenhaus, R.B. (2004) Treatment of T-cell non-Hodgkin's lymphoma. Current Treatment Options in Oncology, 5, 289-303.
16. Friedberg, J.W. (2011) Relapsed/refractory diffuse large B-cell lymphoma. Hematology/the Education Program of the American Society of Hematology, 2011, 498-505.
17. Goy, A., Younes, A., McLaughlin, P., Pro, B., Romaguera, J.E., Hagemeister, F., Fayad, L., Dang, N.H., Samaniego, F., Wang, M., Broglio, K., Samuels, B., Gilles, F., Sarris, A.H., Hart, S., Trehu, E., Schenkein, D., Cabanillas, F. & Rodriguez, A.M. (2005) Phase II study of proteasome inhibitor bortezomib in relapsed or refractory B-cell non-Hodgkin's lymphoma. Journal of Clinical Oncology, 23, 667-675.
18. Guo, Q., Chen, Y. & Wu, Y. (2009) Enhancing apoptosis and overcoming resistance of gemcitabine in pancreatic cancer with bortezomib: a role of death-associated protein kinase-related apoptosis-inducing protein kinase 1. Tumori, 95, 796-803.
19. Hryniuk, W.M. (1987) Average relative dose intensity and the impact on design of clinical trials. Seminars in Oncology, 14, 65-74.
20. Jost, P.J. & Ruland, J. (2007) Aberrant NF-kappaB signaling in lymphoma: mechanisms, consequences, and therapeutic implications. Blood, 109, 2700-2707.
21. Kamat, A.M., Karashima, T., Davis, D.W., Lashinger, L., Bar-Eli, M., Millikan, R., Shen, Y., Dinney, C.P. & McConkey, D.J. (2004) The proteasome inhibitor bortezomib synergizes with gemcitabine to block the growth of human 253JB-V bladder tumors in vivo. Molecular Cancer Therapeutics, 3, 279-290.
22. Kouroukis, C.T., Fernandez, L.A., Crump, M., Gascoyne, R.D., Chua, N.S., Buckstein, R., Turner, R., Assouline, S., Klasa, R.J., Walsh, W., Powers, J. & Eisenhauer, E. (2011) A phase II study of bortezomib and gemcitabine in relapsed mantle cell lymphoma from the National Cancer Institute of Canada Clinical Trials Group (IND 172). Leukaemia & Lymphoma, 52, 394-399.
23. Kuruvilla, J., Nagy, T., Pintilie, M., Tsang, R., Keating, A. & Crump, M. (2006) Similar response rates and superior early progression-free survival with gemcitabine, dexamethasone, and cisplatin salvage therapy compared with carmustine, etoposide, cytarabine, and melphalan salvage therapy prior to autologous stem cell transplantation for recurrent or refractory Hodgkin lymphoma. Cancer, 106, 353-360.
24. Lam, L.T., Wright, G., Davis, R.E., Lenz, G., Farinha, P., Dang, L., Chan, J.W., Rosenwald, A., Gascoyne, R.D. & Staudt, L.M. (2008) Cooperative signaling through the signal transducer and activator of transcription 3 and nuclear factor-{kappa}B pathways in subtypes of diffuse large B-cell lymphoma. Blood, 111, 3701-3713.
25. Luu, T.H., Chow, W.A., Lim, D., Koczywas, M., Frankle, P., Cristea, M., Somlo, G. & Morgan, R.J. (2008) Phase I of fixed-dose-rate gemcitabine in combination with bortezomib in patients with advanced solid tumors. Journal of Clinical Oncology (ASCO Meeting Abstracts), 26(Suppl. 15S), abstract 2563.
26. Luu, T., Chow, W., Lim, D., Koczywas, M., Frankel, P., Cristea, M., Margolin, K., Doroshow, J.H., Somlo, G., Gaur, S., Yen, Y. & Morgan, R.J. (2010) Phase I trial of fixed-dose rate gemcitabine in combination with bortezomib in advanced solid tumors. Anticancer Research, 30, 167-174.
27. Mendler, J.H., Kelly, J., Voci, S., Marquis, D., Rich, L., Rossi, R.M., Bernstein, S.H., Jordan, C.T., Liesveld, J., Fisher, R.I. & Friedberg, J.W. (2008) Bortezomib and gemcitabine in relapsed or refractory Hodgkin's lymphoma. Annals of Oncology, 19, 1759-1764.
28. Ng, M., Waters, J., Cunningham, D., Chau, I., Horwich, A., Hill, M., Norman, A.R., Wotherspoon, A. & Catovsky, D. (2005) Gemcitabine, cisplatin and methylprednisolone (GEM-P) is an effective salvage regimen in patients with relapsed and refractory lymphoma. British Journal of Cancer, 92, 1352-1357.
29. Pahl, H.L. (1999) Activators and target genes of Rel/NF-kappaB transcription factors. Oncogene, 18, 6853-6866.
30. Papandreou, C.N., Daliani, D.D., Nix, D., Yang, H., Madden, T., Wang, X., Pien, C.S., Millikan, R.E., Tu, S.M., Pagliaro, L., Kim, J., Adams, J., Elliott, P., Esseltine, D., Petrusich, A., Dieringer, P., Perez, C. & Logothetis, C.J. (2004) Phase I trial of the proteasome inhibitor bortezomib in patients with advanced solid tumors with observations in androgen-independent prostate cancer. Journal of Clinical Oncology, 22, 2108-2121.
31. Rizvi, M.A., Evens, A.M., Tallman, M.S., Nelson, B.P. & Rosen, S.T. (2006) T-cell non-Hodgkin lymphoma. Blood, 107, 1255-1264.
32. Roncolato, F., Gazzola, A., Zinzani, P.L., Pileri, S.A. & Piccaluga, P.P. (2011) Targeted molecular therapy in peripheral T-cell lymphomas. Expert Review of Hematology, 4, 551-562.
33. Ryan, D.P., Appleman, L.J., Lynch, T., Supko, J.G., Fidias, P., Clark, J.W., Fishman, M., Zhu, A.X., Enzinger, P.C., Kashala, O., Cusack, J. Jr & Eder, J.P. (2006) Phase I clinical trial of bortezomib in combination with gemcitabine in patients with advanced solid tumors. Cancer, 107, 2482-2489.
34. Savage, D.G., Rule, S.A., Tighe, M., Garrett, T.J., Oster, M.W., Lee, R.T., Ruiz, J., Heitjan, D., Keohan, M.L., Flamm, M. & Johnson, S.A. (2000) Gemcitabine for relapsed or resistant lymphoma. Annals of Oncology, 11, 595-597.
35. Voortman, J., Smit, E.F., Kuenen, B.C., Pinedo, H.M., van Groeningen, C., van den Eertwegh, A.J., Brouwer, D., van de Velde, H. & Giaccone, G. (2005) A phase 1B, open-label, dose-escalation study of bortezomib in combination with gemcitabine (Gem) and cisplatin (Cis) in the first-line treatment of patients with advanced solid tumors: preliminary results of a phase IB study. Journal of Clinical Oncology (ASCO Meeting Abstracts), 23(Suppl. 16S), abstract 2103.
36. Voortman, J., Smit, E.F., Honeywell, R., Kuenen, B.C., Peters, G.J., van de Velde, H. & Giaccone, G. (2007) A parallel dose-escalation study of weekly and twice-weekly bortezomib in combination with gemcitabine and cisplatin in the first-line treatment of patients with advanced solid tumors. Clinical Cancer Research, 13, 3642-3651.
37. Wright, C.W., Rumble, J.M. & Duckett, C.S. (2007) CD30 activates both the canonical and alternative NF-kappaB pathways in anaplastic large cell lymphoma cells. Journal of Biological Chemistry, 282, 10252-10262.
38. Zheng, B., Georgakis, G.V., Li, Y., Bharti, A., McConkey, D., Aggarwal, B.B. & Younes, A. (2004) Induction of cell cycle arrest and apoptosis by the proteasome inhibitor PS-341 in Hodgkin disease cell lines is independent of inhibitor of nuclear factor-kappaB mutations or activation of the CD30, CD40, and RANK receptors. Clinical Cancer Research, 10, 3207-3215.
39. Zinzani, P.L., Magagnoli, M., Bendandi, M., Orcioni, G.F., Gherlinzoni, F., Albertini, P., Pileri, S.A. & Tura, S. (1998) Therapy with gemcitabine in pretreated peripheral T-cell lymphoma patients. Annals of Oncology, 9, 1351-1353.
40. Zinzani, P.L., Venturini, F., Stefoni, V., Fina, M., Pellegrini, C., Derenzini, E., Gandolfi, L., Broccoli, A., Argnani, L., Quirini, F., Pileri, S. & Baccarani, M. (2010) Gemcitabine as single agent in pretreated T-cell lymphoma patients: evaluation of the long-term outcome. Annals of Oncology, 21, 860-863.